On May 3, 2022, the research paper entitled "Nanobody-based label-free photoelectro-chemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein" was published in the Analytica Chimica Acta by the team of Professor Li Henan of the School of Chemistry and Chemical Engineering of Jiangsu University and Luoqi Biology. Dr. Wan Yakun and Professor Li Helan of Luoqi Biology are the parallel correspondents. The intellectual property rights of relevant nanoantibodies belong to Luoqi Biology.

On March 8, 2022, with the recovery of the earth, the spring of everything, and the bright sunshine in the afternoon, Shanghai Luoqi Biomedical Technology Co., Ltd. (hereinafter referred to as "Luoqi Biomedical") organized an activity of "improving management, strengthening effective communication and training+cycling".

On January 26, 2022, the China National Drug Administration Drug Evaluation Center (CDE) announced that LQ036, a core drug of Shanghai Luoqi Biomedical Technology Co., Ltd. for the treatment of moderate and severe asthma, is recombinant anti-IL-4R α The application for clinical trial (IND) of single-domain antibody aerosol (Pichia pastoris) was officially approved (Notice No.: 2022LP00124). It only took 2 months from the acceptance of IND to the approval, and there was no supplement.

On December 29, the selection of "Outstanding Innovation and Entrepreneurship Talents in Zhangjiang National Independent Innovation Demonstration Zone" was held for the first time by the Shanghai Promotion of Science and Technology Innovation Center Construction Office and the Shanghai Municipal Human Resources and Social Security Bureau, and the results were officially announced.

On November 26, 2021, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Luoqi Biotechnology") announced that its application for LQ036 (recombinant anti-IL-4Ra single-domain antibody aerosol) IND, which is independently developed and has independent intellectual property rights, was accepted by the National Drug Administration Drug Evaluation Center (CDE) (acceptance number: CXSL2101446). In addition, LQ036 drug is undergoing clinical phase I study in Australia. From the results of the current subjects, LQ036 has good safety.

On November 26, 2021, the business school of Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Luoqi Business School") officially opened! The first training course was held in the conference room of Phase 3 of the International Medical Park. The theme of this training was "Meet a different person and make a better Luoqi". The training invited Dr. Wan Yakun, general manager of Luoqi Biology, to deliver a speech.

At 15:00 on October 15, the celebration of the fourth anniversary of Luoqi Biology kicked off in the 10th building of the third phase of Shanghai Zhoupu Medical Park. Dr. Wan Yakun, the general manager of the company, attended the celebration. Dr. Wan Yakun delivered a speech at the Siqing event: "Looking back on the four years of hard work, the development of Loqi Biology cannot be separated from the efforts and efforts of every colleague. Fortunately, we are from Loqi, and we also hope to meet better Loqi with you!"

Recently, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Luoqi Biotech") announced that its independently developed anti-IL-4R nanoantibody (LQ036 aerosol) drug, which has independent intellectual property rights, has completed the first clinical study on asthma patients in Australia for the first time!

Recently, according to the requirements of the Measures for the Identification and Administration of Pilot and Demonstration Units of Patent Work in Shanghai Enterprises and Institutions (H.ZB [2017] No. 62), Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. was recognized as the "pilot enterprise of patent work in Shanghai in 2021" through expert review and other procedures, and after the study and decision of the Municipal Intellectual Property Office and the Municipal Market Supervision Bureau.

Following the announcement of the completion of the A round financing of 100 million yuan a few days ago, recently, Loqi Biotech announced the completion of the A+round financing of tens of millions of yuan again. This round of financing was led by the Hongyun Fund, a partnership between Huatai Zijin and Alibaba Health. Daoyuan Capital co-invested, and Haoyue Capital continued to serve as the exclusive financial adviser.